The allele distribution of the Ha-ras gene on chromosome llp was analysed by the restriction fragment length 
A polymorphism is observed at the human Haras locus on chromosome 1 Ip based on a variable nuclear tandem repeat. The restriction fragment length polymorphism (RFLP) of the Ha-ras gene arises from changes in the number of this tandemly repeated 28 bp consensus sequence located at the 3' flanking region of the gene. ' The polymorphic DNA segments segregate as codominant markers in a Mendelian fashion and can be used to define classes of alleles of this oncogene: common, intermediate, and rare alleles.2A Especially rare alleles were hypothesised to confer susceptibility to develop particular types of malignant tumours. 34 Two recent studies investigating the Ha-ras allele distribution in patients with colorectal cancer were controversial in their results, but did not use the original definition of alleles.5 6 A conclusive model which summarises several molecular genetic events associated with the known sequence leading from normal colonic mucosa to the hyperproliferative colonic polyps and finally to metastatic colorectal carcinoma was recently presented by Vogelstein.`i The ras oncogenes contribute to this hypothesised multistep process of colorectal cancer development at early stages by hypomethylation and mutations when hyperproliferation has developed.7'-0 Besides this general hypothesis, there are two hereditary syndromes which predispose to colorectal cancer: familial adenomatous polyposis with the responsible gene located on chromosome 5q"' and hereditary non-polyposis colorectal cancer, which has not as yet been linked to any genetic locus (Lynch syndromes I and II). 12 Two disease entities of chronic inflammatory bowel disorders exhibit a quite different potential for the development of colorectal carcinoma. The observed number of extraintestinal cancers in both Crohn's disease and ulcerative colitis is in the range normally expected in the standard population. Ulcerative colitis represents a highly premalignant condition for colorectal carcinoma, particularly when the total colon is involved in combination with a long duration of disease.'3 The risk of cancer of the colon and intestine in Crohn's disease is significantly less increased, estimated as about one third the rate found in ulcerative colitis. '3 14 In general the risk of gastrointestinal cancer in chronic inflammatory bowel disease increases with the duration of the disease. 3 Our aim was to analyse allele frequencies in patients with Crohn's disease and colorectal carcinoma and compare these with the known distribution of alleles.
After the initial report of Krontiris et (Table I ). There was no significant preference of rare alleles when arranged by the anatomical site of the colorectal carcinomas (Fig 4) . In the common group, 46 patients were homozygous for a 1, two for a2, none for a3, and two for a4. (Table II) . These differences were not as great as those for colorectal carcinoma but were placed between Boston cancer free group and Boston cancer group (Table II) . The putative influence of Ha-ras alleles on cancer development must be based on independent alleles. Homozygosity was not seen for any rare allele and no significant differences between colorectal cancer and Crohn's disease patients were detected at the level of the complete Ha-ras genotype. The occurrence ofan individual Ha-ras allele cannot be considered a general predisposition to malignancy -for example, to identify affected people -but could help define subgroups of patients with a special tumour, which could be important in determining the best treatment strategies. Other benign diseases could also be tested for a malignant potential, in cases where the malignant tumour of the involved organ system shows a distribution of Ha-ras alleles that is different to that found normally. Attempts to correlate the Ha-ras allele distribution to clinical or biological characteristics of a particular type of tumour or disease need larger surveys to resolve these issues.
